We are live on ! Find out more
FCM

Farallon Capital Management Portfolio holdings

AUM $17.5B
1-Year Est. Return 50.95%
This Fund
S&P 500
This Quarter Est. Return
-0.05%
1 Year Est. Return
+50.95%
3 Year Est. Return
+148.38%
5 Year Est. Return
+206.05%
10 Year Est. Return
+1,475.31%
AUM
$17.5B
AUM Growth
-$4.53B
Cap. Flow
-$3.73B
Cap. Flow %
-21.26%
Top 10 Hldgs %
49.23%
Holding
203
New
48
Increased
29
Reduced
30
Closed
31

Top Buys

Rank Stock Value
1
AVGO icon
Broadcom
AVGO
+$292M
2
KKR icon
KKR & Co
KKR
+$280M
3
ROIV icon
Roivant Sciences
ROIV
+$248M
4
MA icon
Mastercard
MA
+$138M
5
TMO icon
Thermo Fisher Scientific
TMO
+$133M

Top Sells

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$650M
2
CYBR
CyberArk
CYBR
+$470M
3
CRM icon
Salesforce
CRM
+$334M
4
NDAQ icon
Nasdaq
NDAQ
+$290M
5
RNAM
Avidity Biosciences
RNAM
+$233M

Sector Composition

Rank Sector Weight
1 Healthcare 50.56%
2 Financials 12.21%
3 Technology 11.18%
4 Consumer Discretionary 5.09%
5 Industrials 3.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BEAM icon
26
Beam Therapeutics
BEAM
$2.83B
$242M 1.38%
10,134,696
+71,585
+0.7% +$1.99M
DIS icon
27
Walt Disney
DIS
$170B
$231M 1.32%
2,401,591
-1,724,400
-42% -$182M
MA icon
28
Mastercard
MA
$480B
$217M 1.24%
435,071
+262,400
+152% +$138M
MCK icon
29
McKesson
MCK
$98.5B
$203M 1.16%
234,300
-64,600
-22% -$57.7M
AGIO icon
30
Agios Pharmaceuticals
AGIO
$2.36B
$192M 1.1%
5,684,000
+524,495
+10% +$14.9M
CNTA
31
DELISTED
Centessa Pharmaceuticals
CNTA
$191M 1.09%
4,809,000
-568,068
-11% -$14.5M
TNGX icon
32
Tango Therapeutics
TNGX
$4.65B
$190M 1.08%
9,097,411
-3,964,000
-30% -$55.2M
GRAL
33
GRAIL Inc
GRAL
$3.12B
$168M 0.96%
3,253,684
+911,000
+39% +$70.6M
TYRA icon
34
Tyra Biosciences
TYRA
$1.91B
$137M 0.78%
3,580,818
+1,514,000
+73% +$49M
THC icon
35
Tenet Healthcare
THC
$16.8B
$85.3M 0.49%
452,153
+80,000
+21% +$16.9M
CAH icon
36
Cardinal Health
CAH
$53.5B
$77.8M 0.44%
368,000
-208,000
-36% -$44.8M
PCVX icon
37
Vaxcyte
PCVX
$8.12B
$73.3M 0.42%
1,261,000
+1,256,000
+25,120% +$68.2M
DNTH icon
38
Dianthus Therapeutics
DNTH
$5.77B
$70.2M 0.4%
+836,000
New +$48.4M
BTSG icon
39
BrightSpring Health Services
BTSG
$13.9B
$68.9M 0.39%
1,617,000
+1,595,000
+7,250% +$64.3M
TWST icon
40
Twist Bioscience
TWST
$5.84B
$67.8M 0.39%
1,427,650
+1,420,000
+18,562% +$63.7M
BIDU icon
41
Baidu
BIDU
$36.5B
$49.4M 0.28%
443,785
+128,485
+41% +$17.4M
CGON icon
42
CG Oncology
CGON
$6.34B
$45.6M 0.26%
674,000
+666,000
+8,325% +$37.7M
AZN icon
43
AstraZeneca
AZN
$262B
$44.7M 0.25%
+226,499
New +$43.7M
MRK icon
44
Merck
MRK
$315B
$43.4M 0.25%
+361,000
New +$41.7M
ACHC icon
45
Acadia Healthcare
ACHC
$3.17B
$40.6M 0.23%
+1,736,800
New +$31.4M
WELL icon
46
Welltower
WELL
$172B
$39.5M 0.23%
200,000
-143,000
-42% -$28.3M
IMVT icon
47
Immunovant
IMVT
$8.27B
$38.4M 0.22%
1,546,000
+1,534,000
+12,783% +$39.7M
ENTA icon
48
Enanta Pharmaceuticals
ENTA
$400M
$36.3M 0.21%
2,871,862
+99,600
+4% +$1.34M
JNJ icon
49
Johnson & Johnson
JNJ
$609B
$36.2M 0.21%
+148,000
New +$34.5M
BBNX
50
Beta Bionics
BBNX
$770M
$36.2M 0.21%
3,607,920
-706,000
-16% -$10.4M
1
2
3 4 5

Similar funds

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
Envestnet Portfolio Solutions
Envestnet Portfolio Solutions Chicago, Illinois $18.1B AUM 15% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return

Farallon Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Farallon Capital Management held 203 positions worth $17.5B, down 21% from $22.1B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Farallon Capital Management withdrew a net $3.73B in Q1 2026, closing 31 positions and reducing 30 holdings. Its most notable exit was Exact Sciences, an estimated $650M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 51% of assets, up from 43% a quarter earlier, followed by Financials and Technology.

Against the trend, Farallon Capital Management opened a new position in Dianthus Therapeutics worth $70.2M.

  • Farallon Capital Management's largest Q1 2026 buy was Dianthus Therapeutics: 836,000 shares worth $70.2M.
  • Farallon Capital Management added most to Broadcom in Q1 2026, an estimated $292M increase.
  • Farallon Capital Management's biggest Q1 2026 reduction was Wabtec, cutting an estimated $210M.
  • Farallon Capital Management fully exited Exact Sciences in Q1 2026, selling an estimated $650M.
  • Farallon Capital Management's ten largest holdings make up 49% of its $17.5B portfolio in Q1 2026.
  • Farallon Capital Management opened 48 new positions and closed 31 in Q1 2026.
  • Farallon Capital Management's portfolio value fell 21% quarter-over-quarter to $17.5B.

Based on Farallon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.